Mirum Pharmaceuticals reports Q3 2026 financial results

Item 2.02 Results of Operations and Financial Condition.

On November 3, 2026, Mirum Pharmaceuticals, Inc. (the "Company") issued a press release providing a corporate update and announcing its financial results for the quarter ended September 30, 2026.¹ The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.²

The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

No.

Description

99.1

Press Release dated November 3, 2026

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Mirum Pharmaceuticals, Inc.

Date: November 3, 2026

By: /s/ Christopher Peetz

Christopher Peetz

Chief Executive Officer

Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

– Q3 2026 net product sales of $185.7 million;³ 2026 net product sales guidance increased to $715 million to $720 million

– Received U.S. FDA approval of and launched ATEBRIOZ ® for FOP⁴

– Announced three positive readouts setting up planned regulatory submissions for LIVMARLI ® , ATEBRIOZ and brelovitug⁵

– Received U.S. FDA Orphan Drug Designation for brelovitug in HDV⁶

– Conference call to provide business updates today, November 3 at 1:30 p.m. PT / 4:30 p.m. ET

FOSTER CITY, Calif. – November 3, 2026 – Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today reported financial results for the third quarter 2026 and provided a business update.

"The third quarter was an important period of execution for Mirum, with the approval and launch of ATEBRIOZ and positive Phase 3 results across our late-stage rare liver portfolio," said Chris Peetz, Chief Executive Officer of Mirum. "Positive results from AZURE-1 and additional data we'll be sharing at AASLD reinforce the potential of brelovitug to become an important new treatment for chronic HDV, while EXPAND results support the potential to bring LIVMARLI to more patients living with rare cholestatic liver diseases, including biliary atresia. Together with continued momentum across our commercial business, these milestones position Mirum for